ATE460938T1 - Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion - Google Patents
Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktionInfo
- Publication number
- ATE460938T1 ATE460938T1 AT03812639T AT03812639T ATE460938T1 AT E460938 T1 ATE460938 T1 AT E460938T1 AT 03812639 T AT03812639 T AT 03812639T AT 03812639 T AT03812639 T AT 03812639T AT E460938 T1 ATE460938 T1 AT E460938T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- sexual dysfunction
- dopamine agonists
- morpholine derivatives
- morpholine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0228787A GB0228787D0 (en) | 2002-12-10 | 2002-12-10 | Morpholine dopamine agonists |
GB0308460A GB0308460D0 (en) | 2003-04-11 | 2003-04-11 | Morpholine dopamine agonists |
GB0313606A GB0313606D0 (en) | 2003-06-12 | 2003-06-12 | Morpholine dopamine agonists |
PCT/IB2003/005683 WO2004052372A1 (en) | 2002-12-10 | 2003-12-02 | Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE460938T1 true ATE460938T1 (de) | 2010-04-15 |
Family
ID=32512061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03812639T ATE460938T1 (de) | 2002-12-10 | 2003-12-02 | Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion |
Country Status (37)
Country | Link |
---|---|
EP (1) | EP1572214B1 (de) |
JP (3) | JP3889775B2 (de) |
KR (1) | KR100796102B1 (de) |
AP (1) | AP2005003325A0 (de) |
AR (1) | AR042339A1 (de) |
AT (1) | ATE460938T1 (de) |
AU (1) | AU2003302878B2 (de) |
CA (1) | CA2508262C (de) |
CO (1) | CO5700781A2 (de) |
CR (1) | CR7869A (de) |
CY (1) | CY1110130T1 (de) |
DE (1) | DE60331769D1 (de) |
DK (1) | DK1572214T3 (de) |
EA (1) | EA009589B1 (de) |
EC (1) | ECSP055850A (de) |
ES (1) | ES2339767T3 (de) |
GE (1) | GEP20074272B (de) |
HK (1) | HK1081850A1 (de) |
HN (1) | HN2003000401A (de) |
HR (1) | HRP20050523A2 (de) |
IS (1) | IS7843A (de) |
MA (1) | MA27605A1 (de) |
MX (1) | MXPA05006151A (de) |
MY (1) | MY144338A (de) |
NL (1) | NL1024983C2 (de) |
NO (1) | NO330143B1 (de) |
NZ (1) | NZ540505A (de) |
OA (1) | OA13014A (de) |
PA (1) | PA8591601A1 (de) |
PE (1) | PE20040906A1 (de) |
PL (1) | PL377480A1 (de) |
PT (1) | PT1572214E (de) |
RS (1) | RS51442B (de) |
SI (1) | SI1572214T1 (de) |
TW (1) | TW200423944A (de) |
UY (1) | UY28117A1 (de) |
WO (1) | WO2004052372A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005116027A2 (en) * | 2004-05-26 | 2005-12-08 | Pfizer Limted | Indazole and indolone derivatives and their use as pharmaceuticals |
JP4198183B2 (ja) * | 2004-05-27 | 2008-12-17 | ファイザー・インク | 選択的ドーパミンd3アゴニストとしてのアミノピリジン誘導体 |
GB0502509D0 (en) * | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
GB0700786D0 (en) * | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
JP2013526583A (ja) | 2010-05-21 | 2013-06-24 | リサーチ・トライアングル・インスティチュート | フェニルモルホリンおよびその類似体 |
JP5952267B2 (ja) | 2010-05-21 | 2016-07-13 | リサーチ・トライアングル・インスティチュート | 薬物依存を処置するためのヒドロキシブプロピオン類似体(政府支援研究または開発) |
KR20160097291A (ko) | 2013-12-11 | 2016-08-17 | 에프. 호프만-라 로슈 아게 | 키랄 2-아릴 모폴린의 제조 방법 |
GB2543296A (en) * | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
EP3725768A1 (de) * | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Verfahren zur herstellung von substituierten 2-[2-(phenyl)ethylamino]alkanamid-derivaten |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB851311A (en) * | 1958-04-02 | 1960-10-12 | Geigy Ag J R | Morpholine compounds and their production |
GB9108629D0 (en) * | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
-
2003
- 2003-12-02 PT PT03812639T patent/PT1572214E/pt unknown
- 2003-12-02 SI SI200331801T patent/SI1572214T1/sl unknown
- 2003-12-02 WO PCT/IB2003/005683 patent/WO2004052372A1/en active Application Filing
- 2003-12-02 KR KR1020057010474A patent/KR100796102B1/ko not_active IP Right Cessation
- 2003-12-02 ES ES03812639T patent/ES2339767T3/es not_active Expired - Lifetime
- 2003-12-02 CA CA002508262A patent/CA2508262C/en not_active Expired - Fee Related
- 2003-12-02 DE DE60331769T patent/DE60331769D1/de not_active Expired - Lifetime
- 2003-12-02 AP AP2005003325A patent/AP2005003325A0/xx unknown
- 2003-12-02 RS YUP-2005/0445A patent/RS51442B/en unknown
- 2003-12-02 NZ NZ540505A patent/NZ540505A/en not_active IP Right Cessation
- 2003-12-02 OA OA1200500171A patent/OA13014A/en unknown
- 2003-12-02 GE GEAP20038838A patent/GEP20074272B/en unknown
- 2003-12-02 MX MXPA05006151A patent/MXPA05006151A/es active IP Right Grant
- 2003-12-02 JP JP2005502342A patent/JP3889775B2/ja not_active Expired - Fee Related
- 2003-12-02 EP EP03812639A patent/EP1572214B1/de not_active Expired - Lifetime
- 2003-12-02 AT AT03812639T patent/ATE460938T1/de active
- 2003-12-02 AU AU2003302878A patent/AU2003302878B2/en not_active Ceased
- 2003-12-02 DK DK03812639.7T patent/DK1572214T3/da active
- 2003-12-02 EA EA200500801A patent/EA009589B1/ru not_active IP Right Cessation
- 2003-12-02 PL PL377480A patent/PL377480A1/pl not_active Application Discontinuation
- 2003-12-05 PE PE2003001234A patent/PE20040906A1/es not_active Application Discontinuation
- 2003-12-08 MY MYPI20034690A patent/MY144338A/en unknown
- 2003-12-09 HN HN2003000401A patent/HN2003000401A/es unknown
- 2003-12-09 TW TW092134694A patent/TW200423944A/zh unknown
- 2003-12-09 AR ARP030104524A patent/AR042339A1/es unknown
- 2003-12-10 NL NL1024981A patent/NL1024983C2/nl not_active IP Right Cessation
- 2003-12-10 UY UY28117A patent/UY28117A1/es not_active Application Discontinuation
- 2003-12-10 PA PA20038591601A patent/PA8591601A1/es unknown
-
2005
- 2005-05-12 IS IS7843A patent/IS7843A/is unknown
- 2005-05-26 NO NO20052557A patent/NO330143B1/no not_active IP Right Cessation
- 2005-06-09 HR HR20050523A patent/HRP20050523A2/hr not_active Application Discontinuation
- 2005-06-10 CO CO05056566A patent/CO5700781A2/es not_active Application Discontinuation
- 2005-06-10 CR CR7869A patent/CR7869A/es unknown
- 2005-06-10 MA MA28324A patent/MA27605A1/fr unknown
- 2005-06-10 EC EC2005005850A patent/ECSP055850A/es unknown
-
2006
- 2006-02-17 HK HK06102107.0A patent/HK1081850A1/xx not_active IP Right Cessation
- 2006-06-06 JP JP2006157609A patent/JP3920908B2/ja not_active Expired - Fee Related
- 2006-12-27 JP JP2006352505A patent/JP4624341B2/ja not_active Expired - Fee Related
-
2010
- 2010-04-26 CY CY20101100367T patent/CY1110130T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
NO20052557L (no) | Morfolinderivater for bruk som dopamin-agonister i behandling av blant annet seksuell dysfunksjon. | |
IS7738A (is) | Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum. | |
DE502004002801D1 (de) | Bohrlochbehandlungsmittel, enthaltend ethercarbonsäuren | |
DE602004012154D1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren | |
DE602005012481D1 (de) | 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck | |
DE602005026984D1 (de) | Chinolin-derivate zur behandlung von latenter tuberkulose | |
ATE486597T1 (de) | 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie | |
EA200600203A1 (ru) | Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2 | |
ATE478049T1 (de) | Phosphodiesterase-4-inhibitoren, einschliesslich n-substituierter diarylaminanaloga | |
EA200501928A1 (ru) | Пирролодигидроизохинолины как ингибиторы pde10 | |
EA200300527A1 (ru) | Новые способы лечения синдрома "усталых ног" | |
DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
ATE460166T1 (de) | Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie | |
DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
DK1694122T3 (da) | N-arylhydrazonderivater til fröbehandling | |
DE602006005640D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit | |
HRP20051005A2 (en) | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | |
CL2003002293A1 (es) | Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular. | |
ECSP056057A (es) | Compuestos de benzo[1,2,5]tiadiazole | |
UY28344A1 (es) | Nuevos compuestos | |
DE602006002608D1 (de) | 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit | |
DE60328603D1 (de) | Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren | |
ATE358483T1 (de) | Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen | |
SE0300764L (sv) | Isostatpress för högtrycksbehandling samt förfarande, behållare, anläggning och användning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1572214 Country of ref document: EP |